Y-Biologics, Inc
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
As of 2026-10-10, Y-Biologics, Inc has 10 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2007 and listed on KOSDAQ in 2023, Y-Biologics is an antibody therapeutics developer. It holds the fully human antibody library Ymax®-ABL and a nanobody antibody library derived from it as its core antibody discovery platforms, and its business model centers on out-licensing and contract research organization (CRO) services. Its proprietary pipeline totals seven programs, four next-generation drug candidates and three immunomodulatory monoclonal antibodies, and its flagship candidate Multi-AbKine is a bispecific antibody-cytokine fusion combining the PD-1 inhibitor Acrixolimab (YBL-006), which has completed global Phase 1/2a trials, with an engineered interleukin-2 cytokine variant (IL-2v).
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1/2 · Unknown · 2020-07 · NCT04450901
R&D and key agreements
Source: DART corporate disclosureYmax®-ABL · 플랫폼 기술 · Fully human antibody library platform, also applied to a nanobody antibody library
멀티앱카인(Multi-AbKine) · 암(면역항암) · Bispecific antibody-cytokine fusion built on PD-1 inhibitor Acrixolimab (YBL-006), which completed global Phase 1/2a trials, fused with an engineered IL-2 variant
독자개발 파이프라인(차세대 신약 4종, 면역조절 단일항체 3종) · Seven proprietary pipeline programs in total
Key disclosures
KRX KIND via OpenDART- Management투자판단관련주요경영사항 ([국책과제 선정] 면역함암 항체의약품의 저항성 및 불응성 한계 극복을 위한 이중항체-사이토카인 접합체의 제조기술 개발)2025-07-01
Publications
PubMed · affiliation-matched- LAMMER Kinase Governs the Expression and Cellular Localization of Gas2, a Key Regulator of Flocculation in Schizosaccharomyces pombe.
Journal of microbiology (Seoul, Korea) · 2024-01 · Kang WH, Park YD, Lim JY 외 1
- Therapeutic effect of multiple functional minicircle vector encoding anti-CD25/IL-10/CXCR3 in allograft rejection model.
The Korean journal of internal medicine · 2022-09 · Lim SW, Shin YJ, Cui S 외 4
- Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model.
Endocrinology and metabolism (Seoul, Korea) · 2022-08 · Lee JY, Lee M, Lee DH 외 4
- Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis.
Translational research : the journal of laboratory and clinical medicine · 2021-06 · Kang SE, Park JK, Yoo HJ 외 7
- Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy.
Biomaterials · 2021-04 · Jang S, Song J, Kim N 외 5
- Myostatin Inhibition-Induced Increase in Muscle Mass and Strength Was Amplified by Resistance Exercise Training, and Dietary Essential Amino Acids Improved Muscle Quality in Mice.
Nutrients · 2021-04 · Jang J, Park S, Kim Y 외 8
- MAM domain containing 2 is a potential breast cancer biomarker that exhibits tumour-suppressive activity.
Cell proliferation · 2020-09 · Lee H, Park BC, Soon Kang J 외 3
- Significance of Soluble CD93 in Type 2 Diabetes as a Biomarker for Diabetic Nephropathy: Integrated Results from Human and Rodent Studies.
Journal of clinical medicine · 2020-05 · Lee M, Park HS, Choi MY 외 9
- A bispecific soluble receptor fusion protein that targets TNF-α and IL-21 for synergistic therapy in inflammatory arthritis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020-01 · Park JS, Yoo SH, Lim MA 외 11
- Structural and biochemical analyses reveal ubiquitin C-terminal hydrolase-L1 as a specific client of the peroxiredoxin II chaperone.
Archives of biochemistry and biophysics · 2018-02 · Lee SP, Park CM, Kim KS 외 7
Patents
KIPRIS · applicant-matchedTW · Published · 2025-09 · Application 114134934
PCT · Published · 2025-02 · Application PCT/KR2025/001647
Published · 2025-01 · Application 1020250008498
Published · 2024-09 · Application 1020240120116
CN · Published · 2023-12 · Application 202380087895.4
US · Published · 2023-12 · Application 19142407
EP · Published · 2023-12 · Application 23907877.7
PCT · Published · 2023-12 · Application PCT/KR2023/021443
Published · 2023-10 · Application 1020230145390
PCT · Published · 2023-10 · Application PCT/KR2023/016850
Show 120 more patents
Registered · 2023-03 · Application 1020230038909
CN · Published · 2023-03 · Application 202380030248.X
US · Published · 2023-03 · Application 18850512
EP · Published · 2023-03 · Application 23775361.1
PCT · Published · 2023-03 · Application PCT/KR2023/003977
PCT · Published · 2023-03 · Application PCT/KR2023/003202
Registered · 2022-11 · Application 1020220145950
CN · Published · 2022-11 · Application 202280079185.2
US · Published · 2022-11 · Application 18707591
EP · Published · 2022-11 · Application 22890426.4
PCT · Published · 2022-11 · Application PCT/KR2022/017192
Withdrawn · 2022-09 · Application 1020220116466
PCT · Published · 2022-09 · Application PCT/KR2022/013832
Published · 2022-03 · Application 1020237032971
TW · Published · 2022-03 · Application 111107826
US · Published · 2022-03 · Application 18280068
EP · Published · 2022-03 · Application 22711002.0
PCT · Published · 2022-03 · Application PCT/EP2022/055456
Withdrawn · 2021-08 · Application 1020210103209
Withdrawn · 2021-08 · Application 1020210103208
PCT · Published · 2021-08 · Application PCT/KR2021/010133
Published · 2021-06 · Application 1020237002842
CN · Published · 2021-06 · Application 202310829257.7
CN · Published · 2021-06 · Application 202180050283.9
US · Registered · 2021-06 · Application 17358306
EP · Published · 2021-06 · Application 21829799.2
PCT · Published · 2021-06 · Application PCT/IB2021/000445
Withdrawn · 2021-01 · Application 1020210002592
Registered · 2020-12 · Application 1020200171801
CN · Published · 2020-12 · Application 202080107779.0
TW · Registered · 2020-12 · Application 109143534
US · Published · 2020-12 · Application 18256395
EP · Published · 2020-12 · Application 20964996.1
PCT · Published · 2020-12 · Application PCT/IB2020/061683
Registered · 2020-11 · Application 1020200160099
Withdrawn · 2020-10 · Application 1020200138566
TW · Published · 2020-10 · Application 109135226
Published · 2020-10 · Application 1020200130525
PCT · Published · 2020-10 · Application PCT/KR2020/013805
Rejected · 2020-09 · Application 1020227009289
US · Published · 2020-09 · Application 17640140
EP · Published · 2020-09 · Application 20772003.8
PCT · Published · 2020-09 · Application PCT/EP2020/074825
Withdrawn · 2020-08 · Application 1020200103657
CN · Published · 2020-07 · Application 202080030515.X
US · Registered · 2020-07 · Application 17594523
EP · Published · 2020-07 · Application 20837727.5
PCT · Published · 2020-07 · Application PCT/KR2020/008928
TW · Registered · 2020-06 · Application 109119190
CN · Published · 2020-04 · Application 202080013595.8
US · Registered · 2020-04 · Application 17430144
EP · Published · 2020-04 · Application 20795896.8
PCT · Published · 2020-04 · Application PCT/KR2020/005213
Withdrawn · 2020-03 · Application 1020200038608
CN · Published · 2020-03 · Application 202080001611.1
US · Published · 2020-03 · Application 16964965
EP · Published · 2020-03 · Application 20765639.8
PCT · Published · 2020-03 · Application PCT/KR2020/003100
Registered · 2020-03 · Application 1020200027373
US · Registered · 2020-02 · Application 16792079
Registered · 2019-07 · Application 1020190082492
Registered · 2019-06 · Application 1020190077847
CN · Published · 2019-06 · Application 201980029122.4
US · Registered · 2019-06 · Application 17051630
EP · Published · 2019-06 · Application 19824733.0
PCT · Published · 2019-06 · Application PCT/KR2019/007877
Registered · 2019-04 · Application 1020190049177
Registered · 2019-04 · Application 1020207032356
CN · Published · 2019-04 · Application 201980030028.0
EP · Published · 2019-04 · Application 19785439.1
PCT · Published · 2019-04 · Application PCT/IB2019/052896
US · Registered · 2019-04 · Application 16372190
US · Registered · 2019-04 · Application 16372196
US · Registered · 2019-04 · Application 16372172
PCT · Published · 2018-11 · Application PCT/KR2018/013601
Registered · 2018-09 · Application 1020180107639
CN · Published · 2018-09 · Application 201880068881.7
US · Registered · 2018-09 · Application 16644764
EP · Published · 2018-09 · Application 18853205.5
PCT · Published · 2018-09 · Application PCT/KR2018/010559
Registered · 2017-11 · Application 1020170149362
PCT · Published · 2017-09 · Application PCT/KR2017/010619
Registered · 2017-08 · Application 1020170099672
Registered · 2017-08 · Application 1020170099673
CN · Published · 2017-08 · Application 201780055472.9
CN · Published · 2017-08 · Application 201780055412.7
US · Registered · 2017-08 · Application 16321412
US · Registered · 2017-08 · Application 16321124
EP · Published · 2017-08 · Application 17837300.7
EP · Published · 2017-08 · Application 17837299.1
PCT · Published · 2017-08 · Application PCT/KR2017/008494
PCT · Published · 2017-08 · Application PCT/KR2017/008495
CN · Published · 2017-04 · Application 201780086947.0
US · Published · 2017-04 · Application 16483433
EP · Published · 2017-04 · Application 17896504.2
PCT · Published · 2017-04 · Application PCT/KR2017/004154
Rejected · 2017-03 · Application 1020170031363
Expired · 2017-02 · Application 1020170022270
Withdrawn · 2017-02 · Application 1020170017395
US · Registered · 2016-10 · Application 15337208
Registered · 2015-10 · Application 1020150150871
Withdrawn · 2015-08 · Application 1020150117332
Withdrawn · 2014-04 · Application 1020140049549
Withdrawn · 2014-03 · Application 1020140029828
Withdrawn · 2013-07 · Application 1020130078015
Withdrawn · 2013-07 · Application 1020130078014
Withdrawn · 2012-05 · Application 1020120052927
Withdrawn · 2012-04 · Application 1020120044963
Rejected · 2012-03 · Application 1020120032642
Registered · 2012-01 · Application 1020120001452
Registered · 2012-01 · Application 1020120001460
Registered · 2011-11 · Application 1020110125255
Expired · 2011-09 · Application 1020110094884
Expired · 2011-09 · Application 1020110094885
Rejected · 2011-07 · Application 1020110071937
Expired · 2011-06 · Application 1020110065194
Expired · 2011-06 · Application 1020110054177
Expired · 2010-08 · Application 1020100074604
Rejected · 2010-01 · Application 1020100006209
Registered · 2008-10 · Application 1020080096653
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive4
- OpenAIOAI-SearchBot147
- GoogleGoogleOther41
- PerplexityPerplexityBot10
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 25, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Y-Biologics, Inc and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition